Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C

NCT01908335 is registered in ClinicalTrials.gov with Beijing Kawin Technology Share-Holding Co., Ltd. as lead sponsor.

NCT NCT01908335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C
Lead sponsor
Beijing Kawin Technology Share-Holding Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
July 31, 2014
Enrollment
212 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c